Know Cancer

or
forgot password

Phase I Dose-Escalation Study of Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy


Phase 1
18 Years
N/A
Open (Enrolling)
Both
Bladder Cancer

Thank you

Trial Information

Phase I Dose-Escalation Study of Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy


Inclusion Criteria:



- MSKCC-reviewed pathologically proven diagnosis of primary bladder urothelial
carcinoma without evidence of regional (nodal) or distant spread (cT1-T4a, Nx or N0).

- Karnofsky Performance Scale (KPS) ≥ 70%

- Age ≥18 years old

- Adequately functioning bladder, defined as continent and without the need for an
indwelling catheter

- Absolute neutrophil count (ANC) ≥ 1500/mL; platelets ≥ 100,000/mm3 serum bilirubin <
1.5 x the upper limit of normal (ULN); aspartate aminotransferase (AST) and/alanine
aminotransferase (ALT) ≤ 1.5 × ULN

- Adequate renal function: calculated creatinine clearance > 30 mL/min/1.73 m2 using
the following formula modified Cockcroft and Gault Formula for estimated Creatinine
Clearance

- Patients must be considered able to tolerate systemic chemotherapy and pelvic
radiation therapy.

- Patients must have the ability to understand and the willingness to sign a written
informed consent document

Exclusion Criteria:

- Evidence of distant disease or histologically-proven nodal metastases. Patients with
radiologic evidence of lymphadenopathy must have biopsy proof of N0 status.

- Previous pelvic radiation therapy

- Prior systemic chemotherapy non-cisplatin based neoadjuvant for urothelial carcinoma
(prior intravesical chemotherapy or immunotherapy is permissible)

- Prior cisplatin based neoadjuvant systemic chemotherapy for more than >4 cycles

- Active inflammatory bowel disease (i.e., Crohn's disease or ulcerative colitis)

- Women who are pregnant or lactating

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the dose limiting toxicity and establish the maximal tolerated dose

Outcome Time Frame:

2 years

Safety Issue:

No

Principal Investigator

Marisa Kollmeier, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

10-031

NCT ID:

NCT01104350

Start Date:

April 2010

Completion Date:

April 2017

Related Keywords:

  • Bladder Cancer
  • Bladder
  • Radiotherapy
  • Gemcitabine
  • Chemotherapy
  • 10-031
  • Urinary Bladder Neoplasms

Name

Location

Memorial Sloan Kettering Cancer CenterNew York, New York  10021
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital CenterSleepy Hollow, New York  10591
Memorial Sloan-Kettering at Basking RidgeBasking Ridge, New Jersey  07920
Memorial Sloan-Kettering Cancer Center @ SuffolkCommack, New York  11725
Memorial Sloan-Kettering at Mercy Medical CenterRockville Centre, New York